PATENT CLAIM ANALYSIS

Application Number: 16052918
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2018-11
Patent Classification: ["514", "255040"]

Abstract:
Combinations of a first generation antihistamine for a quick onset with a maintenance dosage amount of a second or third generation antihistamine, along with an additional active agent such as a decongestant, a cough suppressant (an antitussive), a leukotriene receptor antagonist, a 5-lipoxygenase inhibitor, a bronchodilator, an expectorant, or a combination thereof, are disclosed. Methods of using such combinations by concomitant administration, either in the form of a single composition or multiple compositions, are further disclosed.

Claim (Index 4):
The combination of  claim 1 , wherein\n the first generation antihistamine is brompheniramine maleate in an attenuated dosage amount of about 0.4 mg to about 3.6 mg, about 0.5 mg to about 3.0 mg, about 0.75 mg to about 2.5 mg, or about 1.0 mg to about 2.0 mg; chlorpheneramine maleate in an attenuated dosage amount of about 0.2 mg to about 1.75 mg, about 0.5 mg to about 1.5 mg, or about 0.75 mg to about 1.0 mg; clemastine fumarate in an attenuated dosage amount of about 0.268 mg to about 2.4 mg, or about 0.3 mg to about 2.0 mg, or about 0.7 mg to about 1.5 mg; cyproheptadine hydrochloride in an attenuated dosage amount of about 0.4 mg to about 3.6 mg, about 0.6 mg to about 3.0 mg, or about 1.0 mg to about 2.0 mg; diphenhydramine hydrochloride in an attenuated dosage amount of about 2.5 mg to about 23 mg, about 3.5 mg to about 15 mg, about 4.0 mg to about 10 mg, or about 5.0 mg to about 6.25 mg; doxylamine succinate in an attenuated dosage amount of about 0.625 mg to about 6.0 mg, about 1.0 mg to about 4.0 mg, about 1.5 mg to about 3.0 mg, or about 2.0 mg to about 2.5 mg; pheniramine maleate in an attenuated dosage amount of about 2.5 mg to about 23 mg, about 5.0 mg to about 20.0 mg, or about 10.0 mg to about 15.0 mg; promethazine hydrochloride in an attenuated dosage amount of about 1.25 mg to about 8.125 mg, about 2.0 mg to about 6.0 mg, or about 3.0 mg to about 5.0 mg; triprolidine hydrochloride in an attenuated dosage amount of about 0.25 mg to about 1.625 mg, about 0.5 mg to about 1.5 mg, or about 0.75 mg to about 1.0 mg; or a combination thereof; and the second or third generation antihistamine is acrivastine in an amount of about 7.2 mg to about 8.0 mg; cetirizine hydrochloride in an amount of about 9.0 mg to about 10 mg; desloratadine in an amount of about 2.25 to about 5 mg, about 2.25 to about 2.5 mg, or about 4.5 mg to about 5 mg; fexofenadine hydrochloride in an amount of about 54 mg to about 180 mg, about 54 mg to about 60 mg, or about 108 mg to about 120 mg, or about 162 mg to about 180 mg; levocetirizine dihydrochloride in an amount of about 4.5 mg to about 5 mg, loratadine in an amount of about 9.0 mg to about 10 mg, terfenadine in an amount of about 54 mg to about 60 mg, or a combination thereof.

Metadata:
- Claim Count in Document: 4.0
- Percentile: 96.0
- Lexical Diversity: 1.57895
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15281144', '13552684', '10943311', '11672075', '15171231']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7900334214395878
- 35 USC 102 Novelty (BERT): 0.5432640731237747
- Combined Prediction Score: 0.7653564866080065
- Mean Citation Score: 281.863342
- Max Citation Score: 385.43488
- Similarity Product: 381.7430508940125

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test